Patents by Inventor Lauren Pepper MacKenzie

Lauren Pepper MacKenzie has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • Publication number: 20220333134
    Abstract: Disclosed herein are antibodies or antigen binding fragments thereof that specifically bind human CD8. Also disclosed are fusion proteins comprising a Henipavirus glycoprotein G and CD8 antibodies for targeting and transducing cells expressing CD8. Viral vectors and other compositions containing the fusion proteins, as well as methods of using the fusion proteins, are also disclosed.
    Type: Application
    Filed: April 7, 2022
    Publication date: October 20, 2022
    Inventors: Patricia A. CRUITE, Shirisha AMATYA, Hugh HARDING, Lauren Pepper MACKENZIE
  • Publication number: 20220281978
    Abstract: Methods of treating cancer with particular doses of anti-ICOS antibodies are provided.
    Type: Application
    Filed: December 14, 2021
    Publication date: September 8, 2022
    Applicant: Jounce Therapeutics, Inc.
    Inventors: Jason Windham Reeves, Deborah Law, Christopher Harvey, Elizabeth G. Trehu, Lauren Pepper MacKenzie, Amit Deshpande, Jennifer S. Michaelson, Igor Feldman, Sriram Sathyanarayanan
  • Publication number: 20220241328
    Abstract: Provided herein are methods of transducing resting or non-activated T cells using CD8-targeted viral vectors.
    Type: Application
    Filed: January 10, 2022
    Publication date: August 4, 2022
    Applicant: Sana Biotechnology, Inc.
    Inventors: Christopher BANDORO, Patricia CRUITE, Kutlu ELPEK, Akinola Olumide EMMANUEL, Lauren Pepper MACKENZIE, Jagesh Vijaykumar SHAH, Kyle Marvin TRUDEAU
  • Patent number: 11359019
    Abstract: Provided herein are various embodiments relating to antibodies that bind LILRB2. Anti-LILRB2 antibodies can be used in methods to treat disease, for example, cancer.
    Type: Grant
    Filed: July 14, 2020
    Date of Patent: June 14, 2022
    Assignee: Jounce Therapeutics, Inc.
    Inventors: Heather B. Cohen, Lauren Pepper Mackenzie, Donald Raymond Shaffer, Jeffrey Yan-Fei Smith
  • Publication number: 20210353543
    Abstract: Provided herein are lipid particles containing a lipid bilayer enclosing a lumen or cavity, a henipavirus F protein molecule or biologically active portion thereof, and a targeted envelope protein containing a henipavirus envelope attachment glycoprotein G (G protein) or biologically active portion thereof and a binding domain, such as a single domain antibody (sdAb) variable domain. Also provided herein are targeted envelope proteins containing a G protein fused or linked to a binding domain, such as a sdAb variable domain, and polynucleotides encoding such proteins. Also provided are producer cells and compositions containing such targeted lipid particles and methods of making and using the targeted lipid particles.
    Type: Application
    Filed: March 30, 2021
    Publication date: November 18, 2021
    Applicants: Sana Biotechnology, Inc., Flagship Pioneering Innovations V, Inc.
    Inventors: Kyle Marvin TRUDEAU, Christopher BANDORO, Lauren Pepper MACKENZIE, Jagesh Vijaykumar SHAH, Geoffrey A. VON MALTZAHN, Jacob Rosenblum RUBENS, Michael Travis MEE
  • Publication number: 20210340256
    Abstract: Gene expression signatures correlating to ICOS expression levels are provided. Methods of treatment comprising determining ICOS expression levels using gene signatures in patients and administering anti-ICOS antibodies are also provided.
    Type: Application
    Filed: February 5, 2021
    Publication date: November 4, 2021
    Applicant: Jounce Therapeutics, Inc.
    Inventors: Jason Windham Reeves, Igor Feldman, Christopher Harvey, Sriram Sathyanarayanan, Heather Hirsch, Lauren Pepper MacKenzie, Amit Deshpande, Stephen Sazinsky, Jennifer S. Michaelson, Kutlu Goksu Elpek
  • Patent number: 10968277
    Abstract: Gene expression signatures correlating to ICOS expression levels are provided. Methods of treatment comprising determining ICOS expression levels using gene signatures in patients and administering anti-ICOS antibodies are also provided.
    Type: Grant
    Filed: October 21, 2016
    Date of Patent: April 6, 2021
    Assignee: Jounce Therapeutics, Inc.
    Inventors: Jason Windham Reeves, Igor Feldman, Christopher Harvey, Sriram Sathyanarayanan, Heather Hirsch, Lauren Pepper MacKenzie, Amit Deshpande, Stephen Sazinsky, Jennifer S. Michaelson, Kutlu Goksu Elpek
  • Publication number: 20200339690
    Abstract: Provided herein are various embodiments relating to antibodies that bind LILRB2. Anti-LILRB2 antibodies can be used in methods to treat disease, for example, cancer.
    Type: Application
    Filed: July 14, 2020
    Publication date: October 29, 2020
    Inventors: Heather B. COHEN, Lauren Pepper MACKENZIE, Yasmin RAMSAY, Donald Raymond SHAFFER, Jeffrey Yan-Fei SMITH, Kristin Shanea O'MALLEY, Kevin Patrick GUAY
  • Patent number: 10723798
    Abstract: Provided herein are various embodiments relating to antibodies that bind LILRB2. Anti-LILRB2 antibodies can be used in methods to treat disease, for example, cancer.
    Type: Grant
    Filed: December 20, 2018
    Date of Patent: July 28, 2020
    Assignee: Jounce Therapeutics, Inc.
    Inventors: Heather B. Cohen, Lauren Pepper Mackenzie, Yasmin Ramsay, Donald Raymond Shaffer, Jeffrey Yan-Fei Smith
  • Publication number: 20200207856
    Abstract: Provided herein are various embodiments relating to antibodies that bind LILRB2. Anti-LILRB2 antibodies can be used in methods to treat disease, for example, cancer.
    Type: Application
    Filed: March 11, 2020
    Publication date: July 2, 2020
    Inventors: Heather B. Cohen, Lauren Pepper MacKenzie, Yasmin Ramsay, Donald Raymond Shaffer, Jeffrey Yan-Fei Smith, Kristin Shanea O'Malley, Kevin Patrick Guay
  • Patent number: 10618961
    Abstract: Provided herein are various embodiments relating to antibodies that bind LILRB2. Anti-LILRB2 antibodies can be used in methods to treat disease, for example, cancer.
    Type: Grant
    Filed: December 20, 2018
    Date of Patent: April 14, 2020
    Assignee: Jounce Therapeutics, Inc.
    Inventors: Heather B. Cohen, Lauren Pepper Mackenzie, Yasmin Ramsay, Donald Raymond Shaffer, Jeffrey Yan-Fei Smith, Kristin Shanea O'Malley, Kevin Patrick Guay
  • Publication number: 20200024351
    Abstract: Methods of treating cancer with particular doses of anti-ICOS antibodies are provided.
    Type: Application
    Filed: April 2, 2018
    Publication date: January 23, 2020
    Applicant: Jounce Therapeutics, Inc.
    Inventors: Jason Windham Reeves, Deborah Law, Christopher Harvey, Beth G. Trehu, Lauren Pepper MacKenzie, Amit Deshpande, Jennifer S. Michaelson, Igor Feldman, Sriram Sathyanarayanan
  • Publication number: 20190194327
    Abstract: Provided herein are various embodiments relating to antibodies that bind LILRB2. Anti-LILRB2 antibodies can be used in methods to treat disease, for example, cancer.
    Type: Application
    Filed: December 20, 2018
    Publication date: June 27, 2019
    Inventors: Heather B. COHEN, Lauren Pepper MACKENZIE, Yasmin RAMSAY, Donald Raymond SHAFFER, Jeffrey Yan-Fei SMITH, Kristin Shanea O'MALLEY, Kevin Patrick GUAY
  • Publication number: 20180371091
    Abstract: Gene expression signatures correlating to ICOS expression levels are provided. Methods of treatment comprising determining ICOS expression levels using gene signatures in patients and administering anti-ICOS antibodies are also provided.
    Type: Application
    Filed: October 21, 2016
    Publication date: December 27, 2018
    Applicant: Jounce Therapeutics, Inc.
    Inventors: Jason Windham Reeves, Igor Feldman, Christopher Harvey, Sriram Sathyanarayanan, Heather Hirsch, Lauren Pepper MacKenzie, Amit Deshpande, Stephen Sazinsky, Jennifer S. Michaelson, Kutlu Gosku Elpek